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BACKGROUND: The largest growth noted among differentiated thyroid cancer (DTC) diagnosis is in low-risk cancers. Trends in imag-
ing after the diagnosis of DTC are understudied. Hypothesizing a reduction in imaging use due to rising low-risk disease, the authors
evaluated postdiagnosis imaging patterns over time and patient characteristics that are associated with the likelihood of imaging.
METHODS: Using the Surveillance, Epidemiology, and End Results-Medicare database, the authors identified patients diagnosed with
localized, regional, or distant DTC between 1991 and 2009. Medicare claims were reviewed for use of neck ultrasound, iodine-131 (I-
131) scan, or positron emission tomography (PET) scan within 3 years after diagnosis. Trends in imaging use were evaluated using
regression analyses. Multivariable logistic regression was used to estimate the likelihood of imaging based on patient characteristics.
RESULTS: A total of 23,669 patients were included. Compared with patients diagnosed between 1991 and 2000, those diagnosed
between 2001 and 2009 were more likely to have localized disease (P<.001) and tumors measuring <1 cm (P<.001). Use of neck ultra-
sound and I-131 scans increased in patients with localized disease (P .001 and P5.003, respectively), regional disease (P<.001 and
P<.001, respectively), and distant metastasis (P5.001 and P5.015, respectively). Patients diagnosed after 2000 were more likely to
undergo neck ultrasound (odds ratio, 2.15; 95% confidence interval, 2.02-2.28) and I-131 scan (odds ratio, 1.44; 95% confidence interval,
1.35-1.54). Compared with 1996 through 2004, PET scan use from 2005 to 2009 increased 32.4-fold (P.001) in patients with local-
ized disease, 13.1-fold (P<.001) in patients with regional disease, and 33.4-fold (P<.001) in patients with distant DTC. CONCLUSIONS:
Despite an increase in the diagnosis of low-risk disease, the use of postdiagnosis imaging increased among patients with all stages of
disease. The largest growth observed was in the use of PET after 2004. Cancer 2015;121:1387-94. VC 2015 American Cancer Society.
KEYWORDS: differentiated thyroid cancer, surveillance imaging, neck ultrasound, radioiodine scan, positron emission tomography
(PET) scan.
INTRODUCTION
Across a variety of payer systems, the use of advanced imaging techniques has exploded in recent years.1,2 This contributes
to both radiation exposure and increased health care costs.3 One growing area of imaging use is posttreatment surveillance
for malignancy. In the majority of cancers, increased imaging has not translated into improved survival.4,5 In addition,
studies have demonstrated poor adherence to clinical guidelines and a tendency to obtain nonindicated surveillance
imaging.6,7
Thyroid cancer is one of the fastest-growing malignancies in the United States, with the majority of cases comprising
differentiated thyroid cancer (DTC).8,9 Small, low-risk tumors account for the majority of the increase in diagnosis, and
mortality has remained relatively stable.8 Six to 12 months after treatment of DTC, a neck ultrasound and thyroglobulin
level are obtained to evaluate the presence of persistent disease. If thyroglobulin is elevated but there is no abnormality
noted on neck ultrasound, a diagnostic radioiodine (iodine-131 [I-131]) scan is the preferred test; positron emission to-
mography (PET) can be used if the I-131 scan is negative and non–iodine-avid disease is suspected.10-12 Although imaging
has increased in the surveillance of other malignancies, to the best of our knowledge imaging trends after a diagnosis of
thyroid cancer are understudied.
There remains uncertainty regarding the usefulness of imaging in thyroid cancer surveillance, especially among
patients with low-risk disease.13,14 Given the rapid growth in the incidence of DTC, it is important to understand post-
treatment imaging trends, the associated costs, and potential radiation exposure. We hypothesized that, in contrast to
other malignancies, the use of posttreatment imaging in patients with DTC would decrease over time, as a consequence of
the rise in low-risk disease. In the current study, we examined the trends in imaging use after the diagnosis of DTC and
determined the patient characteristics that increased the likelihood of undergoing an imaging study.
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MATERIALS AND METHODS
Data Source and Study Population
The Surveillance, Epidemiology, and End Results (SEER)
database, a project of the National Cancer Institute since
1971, collects cancer incidence, survival, and demo-
graphic data for every cancer reported in 20 geographic
areas throughout the United States. It is the largest
population-based cancer database available in the United
States and covers approximately 28% of the population.15
Beginning in 1991, data from SEER was linked with
Medicare reimbursement claims to create a data set that
included information regarding services performed before
and after a cancer diagnosis.
Data from 25,649 patients with thyroid cancer diag-
nosed from January 1, 1991 to December 31, 2009 were
extracted from the SEER-Medicare database. Only those
with DTC, including tumor histology of papillary, follic-
ular, or Hurthle cell, were retained for the final analysis.
In total, 23,669 patients were included in the final
analysis.
Institutional Review Board approval was not
required because this study used publically available data
and could not be tracked to human subjects.
Measures
Patient age was stratified into 3 Medicare-appropriate
groups: aged <65 years, 65-74 years, and 75 years.
Patient race/ethnicity was categorized by the SEER data-
base as white, black, Hispanic, Asian, North American
Native, or other. Ethnicities of Hispanic, Asian, North
American Native, and other were grouped together as
“other.” As measures of socioeconomic status, the median
household income in the geographic region (<$35,000,
$35,000-$59,999, and $60,000) and the percentage of
the population aged 25 years with only a high school
diploma (<20%, 20-29.9%, and 30%) were collected.
Geographic region was based on Census 2000 tracts,
when available; otherwise, zip codes were used to prevent
missing data. Tumor size was categorized as <1 cm, 1 cm
to 1.9 cm, 2.0 cm to 3.9 cm, and 4.0 cm, according to
definitions used by the American Joint Committee on
Cancer.16 Tumor histology was limited to International
Classification of Disease for Oncology classification codes
for papillary, follicular, and Hurthle cell histology.17
Patients were stratified by their SEER stage at diagnosis as
having localized disease (confined to the thyroid), regional
disease (spread to regional lymph nodes), and distant dis-
ease (metastatic disease).18 The incidence of missing data
was 0.2% for race, education, and income data and 11%
for tumor size. There were no missing data for age, sex,
stage of disease, or histology.
Using Current Procedural Terminology (CPT)
codes, we identified the percentage of patients who under-
went a neck ultrasound, I-131 scan, or PET scan. The
CPT code used to identify neck ultrasound was 76536.
The CPT codes used to identify I-131 scans were 78015,
78016, 78017, 78018, 78020, 78800, 78801, 78802, and
78804. The CPT codes used to identify PET scans were
78810, 78811, 78812, 78813, 78814, 78815, and 78816.
To avoid overrepresenting patients who were diag-
nosed at an earlier time and therefore had longer follow-
up, only imaging studies performed during the first 3
years after diagnosis were included. In addition, because
we did not have claims data for patients diagnosed before
1991, we started our analysis with the year 1993, the first
year in which there were data for patients diagnosed that
year and the 2 prior years. Approximately 60% of neck
ultrasounds, 74% of I-131 scans, and 46% of PET scans
were performed within the 3 years after diagnosis.
Statistical Analysis
To identify changes in patient characteristics over time,
demographics were analyzed in 2 cohorts: patients diag-
nosed from 1991 through 2000 and those diagnosed
between 2001 and 2009. Tumor size and patient age were
categorized using a priori established cutoffs, and all char-
acteristics were compared across the 2 cohorts using the
chi-square test.
For each year from 1993 through 2009, we calcu-
lated the percentage of patients who underwent a neck
ultrasound, I-131 scan, or PET scan. To evaluate the
trends in the use of neck ultrasound and I-131 scans over
time, we regressed percentages of use on the year of the
medical claim. Due to a large increase in use in 2005 for
PET scans, we calculated the fold-increase in percent use,
comparing mean use in 1996 through 2004 with that in
2005 through 2009. A permutation test was used to calcu-
late a P value for the fold-increase.
To identify which patient characteristics influence
the likelihood of undergoing an imaging test, we per-
formed a multivariable logistic regression for each of the 3
imaging tests. For neck ultrasound and I-131 scans, we
included all years from 1991 through 2009, but for PET
scans we included only the years 2005 through 2009 due
to few PET scans being performed before 2005. Covari-
ates in the model included patient age, sex, race, geo-
graphic educational attainment, geographic median
family income, SEER stage, and tumor histology. Year of
diagnosis (1991-2000 or 2001-2009) was included for
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neck ultrasound and I-131 scans, but not for PET scans.
Tumor size was not included as a covariate due to its rela-
tively high degree of missing values. We evaluated the
goodness-of-fit for our models with the Hosmer-
Lemeshow test at the .05 significance level; all 3 models fit
the data well.
All statistical analyses were performed using SAS sta-
tistical software (version 9.3; SAS Institute Inc, Cary,
NC) and R statistical software (version 3.1.1; R Founda-
tion, Vienna, Austria).
RESULTS
The demographics of the study population are shown in
Table 1. Compared with those diagnosed from 1991
through 2000, patients diagnosed with DTC after 2000
were more likely to be older (P<.0001) and to have local-
ized disease (P<.0001) and a smaller tumor size
(P<.0001). In addition, those diagnosed after 2000
tended to come from areas with a lower median house-
hold income (P<.0001) and lower educational achieve-
ment (P<.0001).
The use of imaging in the surveillance of DTC
increased overall during the study period, as summarized
in Figures 1 to 3. In linear regression analysis between
1993 and 2009, there was a significant increase in the use
of ultrasound for those with localized (P<.001), regional
(P<.001), and metastatic (P5 .001) disease. The increase
in I-131 scans was smaller than that for neck ultrasound,
but also increased by linear regression analysis among
patients with localized (P5 .003), regional (P<.001),
and metastatic (P5 .013) disease.
There was a significant increase in the number of
claims for PET scans after the year 2004. Compared with
the period between 1996 and 2004, claims for PET scans
increased 32.4-fold (P<.001) in those with localized
DTC between 2005 and 2009. Those with regional dis-
ease had a 13.1-fold growth in the number of PET scans
performed (P<.001). Finally, PET scan claims for
patients with distant disease increased 33.4-fold
(P<.001).
In multivariable analysis, as shown in Table 2,
patients who were aged 65 years were more likely to
undergo imaging studies than those aged <65 years.
Patients aged 65 to 74 years were more likely to undergo
neck ultrasound (odds ratio [OR], 2.50; 95% confidence
interval [95% CI], 2.35-2.65), I-131 scan (OR, 2.81;
TABLE 1. Differentiated Thyroid Cancer Patient and Tumor Characteristics by Decade of Diagnosis
Year of Diagnosis
1991-2000 N57138 2001-2009 N516,531
Characteristic No. (%) No. (%) P
Age, y <65 3915 (54.8) 6418 (38.8) <.0001
65-74 2000 (28.0) 6419 (38.8)
75 1223 (17.1) 3694 (22.3)
Sex Male 2155 (30.2) 5045 (30.5) .6148
Female 4983 (69.8) 11,486 (69.5)
Race White 5583 (78.4) 13,232 (80.3) <.0001
Black 475 (6.7) 1341 (8.1)
Other 1067 (15.0) 1914 (11.6)
High school
education only, %a
<20% 2306 (33.6) 4507 (27.3) <.0001
20-29.9% 2329 (33.9) 5572 (33.7)
30% 2227 (32.5) 6438 (39.0)
Median household
incomeb
<$35,000 1363 (19.9) 4086 (24.7) <.0001
$35,000-$59,999 3392 (49.4) 7655 (46.4)
$60,000 2105 (30.7) 4774 (28.9)
Stage of disease Localized 4063 (56.9) 10,486 (63.4) <.0001
Regional 2614 (36.6) 5137 (31.1)
Distant 461 (6.5) 908 (5.5)
Histology Papillary 5920 (82.9) 14,196 (85.9) <.0001
Hurthle cell 405 (5.7) 893 (5.4)
Follicular 813 (11.4) 1442 (8.7)
Tumor size, cm <1 1769 (29.2) 5217 (34.7) <.0001
1-1.9 1337 (22.1) 3660 (24.3)
2-3.9 1890 (31.2) 3764 (25.0)
4 1059 (17.5) 2390 (15.9)
a Percentage of individuals aged 25 years in the geographic area with only a high school education.
bMedian household income by geographic region.
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95% CI, 2.64-3.00), and PET scan (OR, 1.54; 95% CI,
1.34-1.77). A similar effect was observed for those aged
75 years, with a higher likelihood of undergoing neck
ultrasound (OR, 2.10; 95% CI, 19.6-2.26), I-131 scan
(OR, 1.80; 95% CI, 1.67-1.95), and PET scan (OR,
1.80; 95% CI, 1.54-2.09). Women were more likely than
men to undergo neck ultrasound (OR, 1.35; 95% CI,
1.27-1.43), but were less likely to have a PET scan (OR,
0.73; 95% CI, 0.65-0.82). Compared with white individ-
uals, blacks were less likely to undergo a neck ultrasound
(OR, 0.81; 95% CI, 0.73-0.90), I-131 scan (OR, 0.88;
95% CI, 0.79-0.99), or PET scan (OR, 0.63; 95% CI,
0.49-0.80). Other nonwhite individuals were also found
to be less likely to undergo neck ultrasound (OR, 0.86;
95% CI, 0.79-0.93) and I-131 scan (OR, 0.88; 09% CI,
0.81-0.96).
SEER stage was found to be significantly associated
with the likelihood of having an imaging claim. Patients
with regional disease were more likely to have a claim for
neck ultrasound compared with those with localized dis-
ease (OR, 1.20; 95% CI, 1.13-1.27), whereas those with
distant disease were less likely (OR, 0.74; 95% CI, 0.66-
0.83). Patients with both regional DTC (OR, 2.65; 95%
CI, 2.50-2.82) and distant disease (OR, 2.12; 95% CI,
1.88-2.39) were more likely to undergo an I-131 scan.
Again, patients with regional disease (OR, 2.05; 95% CI,
1.82-2.30) and distant DTC (OR, 3.72; 95% CI, 3.03-
4.56) were also more likely to undergo a PET scan. His-
tology was not found to be a clinically significant factor
with regard to the use of imaging, except for an increased
tendency to obtain PET scans (OR, 1.54; 95% CI, 1.24-
1.91) among patients with Hurthle cell carcinomas. Con-
trolling for other patient characteristics, patients diag-
nosed from 2001 through 2009 were more likely to
undergo a neck ultrasound than those diagnosed from
1991 through 2000 (OR, 2.15; 95% CI, 2.02-2.28).
Patients diagnosed after 2000 were also more likely to
undergo an I-131 scan (OR, 1.44; 95%CI, 1.35-1.54).
DISCUSSION
We hypothesized that imaging use after a diagnosis of thy-
roid cancer would decrease over time due to the rise in
low-risk disease. Using the SEER-Medicare database, we
unexpectedly found that there was a significant increase in
the use of surveillance imaging studies over the past 20
Figure 2. Imaging claims in patients with regional differenti-
ated thyroid cancer are shown by year. US indicates ultra-
sound; I-131, iodine-131; PET, positron emission tomography.
Figure 3. Imaging claims in patients with distant differenti-
ated thyroid cancer are shown by year. US indicates ultra-
sound; I-131, iodine-131; PET, positron emission tomography.
Figure 1. Imaging claims in patients with localized differenti-
ated thyroid cancer are shown by year. US indicates ultra-
sound; I-131, iodine-131; PET, positron emission tomography.
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years across all stages of disease. This is true for neck ultra-
sound, I-131 scans, and PET scans. The most dramatic
increase was noted in the use of PET after 2004. SEER
stage at diagnosis appears to have the largest impact on the
likelihood of undergoing an imaging test. However, we
still observed an increased use of imaging after controlling
for other patient characteristics, including stage of disease
at diagnosis.
It has become apparent that there is more reliance
on advanced imaging studies in the practice of medicine.
Initially, this was believed to be confined to the fee-for-
service model.2 However, an integrated health system
resulted in an approximate doubling of computed tomog-
raphy (CT) scans and near-tripling of magnetic resonance
imaging (MRI) from 1997 through 2006.1 Consistent
with the findings of the current study, nuclear medicine
studies have experienced slower growth, except for PET
and PET/CT scans. A striking increase was observed in
the number of PET scans performed after the year 2004
in a non-Medicare population.1 The greatest growth in
imaging use has been noted among older enrollees, but
was observed in all age groups.1
Imaging studies in patients with malignancy are very
commonly performed and are increasing. Greater than
95% of patients with advanced malignancy will undergo a
high-cost diagnostic imaging procedure.19 Studies have
demonstrated a rise in imaging being performed in
patients after treatment of a malignancy. A large increase
in the use of MRI scans was noted among patients treated
for hepatocellular carcinoma from 1998 to 2005.5 In
patients with pancreatic cancer, the number of CT, MRI,
and PET scans performed in the 5 years after surgical
resection more than doubled from 1991 to 2005.20 Simi-
lar increases occurred in patients after resection of colo-
rectal liver metastasis.4 PET scanning is being rapidly
adapted in the evaluation of malignancies; 65.3% of
patients with non-small cell lung cancer underwent a PET
scan from 2005 through 2007, compared with 6.3% of
patients between 1998 and 2000.21
To the best of our knowledge, no study to date
has demonstrated a clear mortality benefit for surveil-
lance imaging. CT after surgical resection of pancreatic
cancer did not appear to improve survival in patients
receiving annual surveillance.20 Similar results were
noted among patients with hepatocellular carcinoma
and colorectal cancer with liver metastasis.4,5 PET was
not found to be a useful tool for the detection of mela-
noma recurrence in patients at low risk, and did not
confer any additional mortality benefit beyond yearly
CT scan in patients at high risk.22
TABLE 2. Association Between Patient and Tumor Characteristics and Likelihood of an Imaging Claim
Neck Ultrasound I-131 Scan PET Scana
Characteristic OR (95% CI) P OR (95% CI) P OR (95% CI) P
Age, y <65 1 [reference] 1 [reference] 1 [reference]
65-74 2.50 (2.35-2.65) <.0001 2.81 (2.64-3.00) <.0001 1.54 (1.34-1.77) <.0001
75 2.10 (1.96-2.26) <.0001 1.80 (1.67-1.95) <.0001 1.80 (1.54-2.09) <.0001
Sex Male 1 [reference] 1 [reference] 1 [reference]
Female 1.35 (1.27-1.43) <.0001 1.10 (1.03-1.17) .0028 0.73 (0.65-0.82) <.0001
Race White 1 [reference] 1 [reference] 1 [reference]
Black 0.81 (0.73-0.90) <.0001 0.88 (0.79-0.99) .0268 0.63 (0.49-0.80) .0002
Other 0.86 (0.79-0.93) .0002 0.88 (0.81-0.96) .0049 0.89 (0.74-1.06) .1904
High school
education only, %b
<20% 1 [reference] 1 [reference] 1 [reference]
20-29.9% 1.02 (0.95-1.10) .5241 0.99 (0.92-1.06) .7290 1.02 (0.88-1.18) 0.8027
30% 1.11 (1.03-1.20) .0062 1.13 (1.05-1.23) .0019 0.97 (0.83-1.13) 0.6838
Median household
incomec
<$35,000 1 [reference] 1 [reference] 1 [reference]
$35,000-$59,999 0.90 (0.84-0.97) .0041 1.03 (0.95-1.10) .4829 0.84 (0.73-0.97) .0161
$60,000 1.16 (1.07-1.26) .0005 1.09 (1.00-1.19) .0419 1.02 (0.86-1.20) .8537
Stage of disease Localized 1 [reference] 1 [reference] 1 [reference]
Regional 1.20 (1.13-1.27) <.0001 2.65 (2.50-2.82) <.0001 2.05 (1.82-2.30) <.0001
Distant 0.74 (0.66-0.83) <.0001 2.12 (1.88-2.39) <.0001 3.72 (3.03-4.56) <.0001
Histology Papillary 1 [reference] 1 [reference] 1 [reference]
Follicular 0.89 (0.81-0.97) .0121 1.14 (1.04-1.25) .0070 0.84 (0.69-1.03) .0879
Hurthle cell 0.91 (0.81-1.03) .1308 1.21 (1.07-1.36) .0021 1.54 (1.24-1.91) <.0001
Decade of diagnosis 1991-2000 1 [reference] 1 [reference]
2001-2009 2.15 (2.02-2.28) <.0001 1.44 (1.35-1.54) <.0001
Abbreviations: 95% CI, 95% confidence interval; I-131, iodine-131; OR, odds ratio; PET, positron emission tomography.
a Includes patients diagnosed between 2005 and 2009.
b Percentage of individuals aged 25 years in geographic area with only a high school education.
cMedian household income by geographic region.
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There is often poor adherence to recommendations
for surveillance imaging. Studies in patients with early-
stage breast cancer found a high incidence of nonrecom-
mended imaging tests (such as MRI) for surveillance;
however, physicians often fail to obtain recommended
mammograms.7 There has been a sharp increase in the
number of nonrecommended CT and PET scans per-
formed among patients with colorectal cancer from 2001
through 2006.6 In men with low-risk prostate cancer,
34% reportedly underwent nonrecommended bone scans
or CT scans.23 It is interesting to note that only 60% of
men with high-risk prostate cancer, for whom they are
recommended, had these tests.
There is a variety of imaging modalities used for
posttreatment surveillance among patients with DTC.
Neck ultrasound is useful to detect recurrent disease, but
does not detect distant metastasis.24 I-131 scans can iden-
tify distant disease, but have been shown to have limited
value in the setting of low thyroglobulin levels, even in
high-risk patients.13 In addition, the sensitivity of diag-
nostic I-131 scans in patients with mildly elevated stimu-
lated thyroglobulin is low.25 PET has demonstrated the
ability to detect small-volume non–iodine-avid disease. A
significant percentage of patients with a detectable thyro-
globulin level <10 ng/mL are found to have evidence of
disease on PET scan.26
However, the significance of the thyroid cancer
detected by PET scan is debated. To our knowledge, there
is a lack of evidence regarding the effect of PET scans on
progression-free survival among patients with DTC.27,28
Others have questioned whether PET provides additional
information beyond neck ultrasound and CT scan.14
Although PET-positive disease has been shown to be a
poor prognostic indicator, this effect is strongest in
patients with metastatic, large-volume disease.29,30
Patients with small-volume, regional, PET-positive dis-
ease continue to have an excellent prognosis.
We found a large increase in the use of PET after
the year 2004. In October 2003, Medicare approved the
use of PET scans for patients treated with thyroidectomy
and radioactive iodine ablation with a thyroglobulin level
>10 ng/mL and a negative I-131 scan. In January 2005,
Medicare expanded its coverage of PET scans under the
Coverage with Evidence Development program to
include indications for “diagnosis, other staging, restag-
ing and monitoring response to treatment.”31 Part of the
increase in the use of PET may be related to this
expanded Medicare coverage. However, the same increase
in PET scan use has been demonstrated in patients with-
out thyroid cancer or Medicare coverage, suggesting there
may be additional factors, such as improved
accessibility.2,21
One inherent limitation of the current study is the
lack of patient-level data available in large databases.
There is limited information regarding cancer recurrence,
iodine avidity, and patient preference, all of which influ-
ence imaging decisions. Another limitation is the restric-
tion in the current study to 3 imaging modalities:
ultrasound, I-131 scan, and PET. Billing information is
not a reliable source of the indication for imaging tests.
Many CT and MRI scans are also being performed in
patients with DTC. However, we were concerned that
these scans are more likely to be performed for indications
other than thyroid cancer. Therefore, we focused on 3
imaging modalities that we believed would be most spe-
cific to DTC surveillance. A third perceived limitation
would be the absence of American Joint Committee on
Cancer TNM staging. We used SEER stage in the current
study because TNM stage is not available for patients
diagnosed before 2004. Including patients diagnosed
before 2004 was essential because of our emphasis on
trends in imaging use over time.
Using SEER-Medicare, the current study cohort
included patients diagnosed after 1991 who were Medi-
care enrollees, resulting in smaller numbers compared
with the SEER database alone. The cohort in the current
study was primarily aged 65 years. Patients aged <65
years who are covered by Medicare are likely to have sig-
nificant other comorbidities and are not generalizable to a
younger DTC population. In addition, because the data
are linked to Medicare billing records, there may be
underreporting of imaging tests performed. For example,
if physicians perform bedside ultrasound or patients have
secondary insurance covering the imaging test, there
would be no documentation in the Medicare database.
However, with regard to capturing I-131 scans, the per-
centage of patients in the current study with claims for an
I-131 scan was similar to prior reported rates of radioac-
tive iodine ablation after thyroidectomy.32-34
Despite these limitations, there is strong evidence
that SEER-Medicare is a valid tool for the evaluation of
posttreatment surveillance imaging. Prior studies have
confirmed the usefulness of the SEER-Medicare data to
identify clinical events, such as a cancer treatment or sur-
veillance after cancer treatment.35,36 In fact, many studies
of posttreatment surveillance in patients with other malig-
nancies have been performed using the SEER-Medicare
database.4,5,20,21,37 The population in the SEER-
Medicare data set has also been found to be generalizable
to the elderly American population.38 Although the
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current study cohort was primarily aged65 years, this is
an important patient population to study because the fast-
est increase in thyroid cancer incidence has been observed
in this age group.39 In addition, the largest growth in gen-
eral imaging use has occurred in older patients, although
it has been demonstrated in younger patients as well.1
This also is most likely true for thyroid-specific imaging.
Therefore, we believe a similar increase in imaging would
be observed in a younger thyroid cancer population.
DTC is one of the fastest growing malignancies in
the United States, resulting in a variety of providers deliv-
ering posttreatment surveillance, including endocrinolo-
gists, oncologists, surgeons, nuclear medicine specialists,
and primary care physicians.9 Although there are specific
guidelines and recommendations for posttreatment sur-
veillance imaging, there is evidence that compliance with
published guidelines is often low.6,7 Work performed to
evaluate surveillance imaging among patients with other
malignancies has suggested small mortality benefits, if
any.4,5,20,22 We demonstrated the increased use of imag-
ing over time despite the diagnosis of smaller, more lim-
ited, low-risk thyroid cancer. Although many of the
themes presented in the current study are true for other
malignancies, the overuse of imaging is highlighted by the
increased use in patients with this relatively indolent
malignancy. Greater imaging use clearly contributes to
increased costs. Specific to thyroid cancer, increased imag-
ing may identify low-volume recurrent disease that is
unlikely to be clinically significant, leading to heightened
patient anxiety and potentially unnecessary interventions.
Growing health care costs underscore the importance of
identifying those patients most likely to benefit from
additional testing and determining when it can be
avoided.
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